---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-021311"
form_type: "8-K"
ticker: "LMAT"
cik: "0001158895"
company_name: "LEMAITRE VASCULAR INC"
filed_at: "2021-09-01T23:59:59+00:00"
generated_at: "2026-06-29T06:22:01.396129+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# LeMaitre Vascular assumes EU MDR CE Mark responsibility for CardioCel/VascuCel; costs deducted from $2M earn-out

## Summary
- On August 28, 2021, LeMaitre amended its 2019 asset purchase agreement with Anteris Technologies (formerly Admedus).
- LeMaitre will seek CE Mark certification under EU MDR for CardioCel and VascuCel biologic patches.
- Costs of obtaining CE Mark approvals will be deducted from the $2 million earn-out payable to Anteris.
- 75% of earn-out paid after CardioCel MDR certification; 25% after VascuCel MDR certification.
- Transition services agreement extended by nine months to July 11, 2023.

## SEC filing metadata
- accession: 0001437749-21-021311
- form_type: 8-K
- ticker: LMAT
- cik: 0001158895
- company_name: LEMAITRE VASCULAR INC
- filed_at: 2021-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158895/000143774921021311/0001437749-21-021311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158895/000143774921021311/lmat20210831_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-021311
- JSON: https://secwatch.observer/filing/0001437749-21-021311.json
- Plain text: https://secwatch.observer/filing/0001437749-21-021311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.